We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current NWBO market cap is 547.51M. The company's latest EPS is USD -0.0541 and P/E is -3.14.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 2.41M | 1.29M | 1.01M | 1.68M | 1.93M |
| Operating Income | -27.46M | -86.61M | -52.7M | -67.18M | -55.51M |
| Net Income | -20.3M | -529.82M | 179.13M | -105.03M | -64.37M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 9.13M | 32.9M | 40.16M | 31.32M | 27.87M |
| Total Liabilities | 52.7M | 395.85M | 164.15M | 136.37M | 74.92M |
| Total Equity | -43.57M | -362.95M | -123.99M | -128.1M | -65.77M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -31.86M | -32.09M | -38.3M | -52.78M | -53.64M |
| Investing | -360k | -8.14M | -6.02M | -2.9M | -3.44M |
| Financing | 9.95M | 52.7M | 48.13M | 41.97M | 52.76M |
| Market Cap | 547.51M |
| Price to Earnings Ratio | -3.14 |
| Price to Sales Ratio | 106.25 |
| Price to Cash Ratio | 94.44 |
| Price to Book Ratio | -4.3 |
| Dividend Yield | - |
| Shares Outstanding | 1.19B |
| Average Volume (1 week) | 1.48M |
| Average Volume (1 Month) | 1.7M |
| 52 Week Change | -7.98% |
| 52 Week High | 1.11 |
| 52 Week Low | 0.4001 |
| Spread (Intraday) | 0.01 (2.11%) |
| Company Name | Northwest Biotherapeutics Inc (QB) |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https:// |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
